Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer

Case Reports in Oncology

Volumn 6, Issue 2, 2013, Pages 430-433

  Kuriyama, Yuka ^a   Kim, Young Hak ^a   Nagai, Hiroki ^a   Ozasa, Hiroaki ^a   Sakamori, Yuichi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Anaplastic lymphoma kinase; Beyond progressive disease; Crizotinib; Disease flare; Non small cell lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; ERLOTINIB; MICROTUBULE ASSOCIATED PROTEIN; NAVELBINE; PACLITAXEL; MICROTUBULE ASSOCIATED PROTEIN 4;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CHEMORADIOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE EXACERBATION; DRUG RESPONSE; DRUG WITHDRAWAL; ECHINODERM; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INDUCTION CHEMOTHERAPY; LUNG ADENOCARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; RETREATMENT; SMOKING; THORAX RADIOGRAPHY; TUMOR VOLUME; CANCER RECURRENCE; DYSPHAGIA; DYSPNEA; ENDOBRONCHIAL ULTRASONOGRAPHY; LUNG CANCER; LUNG METASTASIS; LUNG NODULE; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MIDDLE AGED; TRANSBRONCHIAL ASPIRATION; TREATMENT RESPONSE;

EID: 84885636436     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000354756     Document Type: Article

References (6)

1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M: Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859.
2. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.
3. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150-5155.
4. Pop O, Pirvu A, Toffart AC, Moro-Sibilot D: Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thorac Oncol 2012;7:e1-e2.
5. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W: New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011;17:5530-5537.
6. Kim YH, Fukuhara A, Mishima M: Should epidermal growth factor receptor-tyrosine kinase inhibitor be continued beyond progressive disease? Case Rep Oncol 2011;4:470-474.